The chimeric PD‐1 engineered CAR‐T cells displayed an increased secretion of cytokines, expanded populations of effector T cells, stronger anti‐tumour activity and enhanced protection against re‐challenged tumours. This evidence concerns the gene PDCD1 and neoplasm.